B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
NRC
NRC HealthCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$21.50
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-31
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+59.2
Score
AI commentary
News tone is mildly positive after the Q2 release, led by TRCV growth and bookings commentary, but the financial profile remains mixed because GAAP earnings and free cash flow were weak. No verified post-print analyst revisions were available, and social, options, short-interest, and employee data were not provided. The RankAlpha anchor was $18.91 on July 30; the live finance feed showed $19.11 intraday on July 31, without evidence attributing that move to earnings.
RankAlpha Sentiment Codex - 2026-07-31
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-28eventQ2 2026 results show recurring-growth strengthMedium impact
NRC reported Q2 TRCV of $151.9 million, up 11% year over year, revenue up 4% to $35.4 million, adjusted net income of $6.9 million, and adjusted EBITDA of $9.4 million. Management also cited strong execution, product commercialization, and the strongest Governance Institute bookings in seven years. [#SEC-8K-2026-07-28]
2027-07-31catalystRecurring-contract growth and product commercializationHigh impact
Sustained TRCV growth and continued commercialization of product innovations could support a stronger second half, but the thesis remains dependent on converting recurring-value growth into revenue, margins, and cash flow. [#SEC-8K-2026-07-28]
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-31 • Updated nightlySource: Internal modelMethodology